TICKERNERD
Menu
RGENRGENHealthcare · Medical Instruments & Supplies

RGEN Stock Forecast: Repligen Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$177
−0.73% on the day

The 23 Wall Street analysts covering Repligen Corp. hold a median 12-month price target of $185 — +4.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$10.0B
Ticker Nerd rank
92 / 100
Median analyst target
$185
Analysts covering
23
Revenue$204.1M+11.9% y/y
Operating income$19.0M
Net income$5.0M
Free cash flow$26.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.1%
1M
+6.5%
YTD
+8.0%
1Y
+42.2%
From 52W high
−2.8%
From 52W low
+72.0%
$103
$182
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Repligen Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
88
Momentum
83
Quality
82
Growth
80
Value
73
Volatility
68
Accruals
65
Issuance
57
Size
15

Revisions (88): Analysts have, on balance, been raising their forecasts.

Issuance (57): The company has been issuing shares or taking on financing, diluting existing holders.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200Oct 25Jan 26Apr 26Jul 26RGENHigh $225Median $185Low $145

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
19 Buy4 Hold0 Sell
Low $145Median $185High $225

The green dot is the last close — the median target sits +4.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026UBSMaintainsBuy$195 → $225
30 July 2026Wells FargoMaintainsOverweight—
30 July 2026Wells FargoMaintainsOverweight$180 → $185
29 July 2026JP MorganMaintainsOverweight—
29 July 2026JP MorganMaintainsOverweight$165 → $175
7 July 2026BenchmarkUpgradeBuy—
7 July 2026BenchmarkUpgradeBuy$185
6 July 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$150 → $160
3 June 2026HSBCMaintainsBuy—
2 June 2026Wolfe ResearchAssumesOutperform$145
15 May 2026RBC CapitalReinstatesOutperform$160
6 May 2026BarclaysMaintainsOverweight—
6 May 2026JP MorganMaintainsOverweight—
20 Apr 2026Canaccord GenuityMaintainsHold—
17 Apr 2026Roth CapitalInitiatesBuy—
14 Apr 2026BarclaysMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Repligen Corp. returned +42.2% against +16.3% for the S&P 500, dividends included.

RGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140Oct 25Jan 26Apr 26Jul 26RGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.1%
Analysts raising
20
Analysts cutting
0
Fundamentals

Repligen Corp. (RGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
242.3×

Cheaper than 3% of US stocks

Price / sales
12.7×

Cheaper than 13% of US stocks

Price / book
4.7×

Cheaper than 22% of US stocks

EV / EBITDA
69.0×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
11.9%

Higher than 57% of US stocks

Earnings growth (YoY)
−66.3%

Higher than 7% of US stocks

Gross margin
53.9%

Higher than 67% of US stocks

Operating margin
9.3%

Higher than 63% of US stocks

Net margin
5.3%

Higher than 61% of US stocks

Returns & dividend
Return on equity
2.0%

Higher than 47% of US stocks

Return on assets
1.4%

Higher than 54% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Repligen Corp. (RGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Repligen Corp. has a market value of $10.0B and an enterprise value of $9.9B.

  • Revenue in the twelve months to 30 June 2026: $785.1M. The latest quarter grew 11.9% year on year.

  • Net income over the same four quarters: $41.5M, a 5.3% net margin.

  • Diluted earnings per share, trailing twelve months: $0.73.

  • Free cash flow in the twelve months to 30 June 2026: $110.2M, after $1.8M of capital spending.

  • Shares outstanding: 56.4M.

  • Trailing P/E: 242.3×; forward P/E: 66.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Repligen Corp. employs 2,000 people — $393K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

RGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
RGENRepligen Corp.$10.0B
92
ALGNAlign Technology, Inc.$10.6B
83
AVTRAvantor, Inc.$10.6B
81
COOThe Cooper Cos., Inc.$10.8B
70
BAXBaxter International, Inc.$11.7B
90
ATRAptarGroup, Inc.$8.2B
51
SOLVSolventum Corp.$15.4B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Repligen Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RGEN news & analysis

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Business Wire · 10 Sept 2026neutral

Law firm Kahn Swick & Foti, LLC announced it is investigating the proposed sale of BioLife Solutions, Inc. to Repligen Corporation, under which BioLife shareholders would receive $11.25 in cash and 0.1442 shares of Repligen common stock per share. The firm is seeking to determine the adequacy of the price and process in the proposed transaction.

Why it matters — This matters for RGEN watchers because a shareholder investigation could affect the timeline or terms of Repligen's proposed acquisition of BioLife Solutions.

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 9 Sept 2026neutral

Repligen Corporation presented at the Wells Fargo 21st Annual Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports the availability of the presentation transcript from the event.

Why it matters — A RGEN watcher would be interested in the transcript to review what management discussed at a major industry healthcare conference.

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Zacks Investment Research · 27 Aug 2026positive

Repligen Corp. reported earnings 30 days ago, and its stock has risen 27.7% since that announcement. The article examines what may be next for the company following this earnings-driven gain.

Why it matters — Repligen watchers would track this significant post-earnings share price movement to understand the market's reaction to the company's latest results.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Investment Research · 27 Aug 2026neutral

Zacks Investment Research highlighted Halozyme, Repligen, Iovance, Arcutis, and Precigen in its Industry Outlook article. The piece covers these companies as part of a broader industry analysis.

Why it matters — RGEN watchers would care because the article provides industry-level context and visibility for Repligen alongside its peers in the biopharma sector.

5 Biotech Stocks Worth Adding to Your Portfolio Now

Zacks Investment Research · 26 Aug 2026positive

A Zacks Investment Research article highlights that new drug approvals and pipeline progress should maintain momentum in the Biomedical and Genetics industry despite economic uncertainty, and names Repligen (RGEN) among five biotech stocks positioned with a strong portfolio and solid pipeline progress.

Why it matters — RGEN followers would note the article's favourable view of the company's portfolio and pipeline within the broader biotech sector.

FAQ

Frequently asked questions about RGEN stock

What is the RGEN stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Repligen Corp. have a median 12-month price target of $185, with estimates ranging from $145 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RGEN stock a buy right now?

Of the 23 analysts covering Repligen Corp., 19 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Repligen Corp. 92 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RGEN?

As at 19 Sept 2026, Repligen Corp. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (88 of 100).

Will RGEN stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +4.6% from the last close, and Ticker Nerd's factor model ranks Repligen Corp. 92 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RGEN stock forecast for 2030?

No analyst covering Repligen Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $225 over the next 12 months.

How has RGEN stock performed over the past year?

Repligen Corp. returned +42.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Repligen Corp. do?

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflows across filtration, fluid management, chromatography, process analytics, and single-use technologies.

What is the latest news on RGEN?

The most recent item we track (Business Wire, 10 Sept 2026): "BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS". Law firm Kahn Swick & Foti, LLC announced it is investigating the proposed sale of BioLife Solutions, Inc. to Repligen Corporation, under which BioLife shareholders would receive $11.25 in cash and 0.1442 shares of Repligen common stock per share. The firm is seeking to determine the adequacy of the price and process in the proposed transaction.

Company

About Repligen Corp.

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflows across filtration, fluid management, chromatography, process analytics, and single-use technologies. Its products are used by biopharmaceutical companies and contract development and manufacturing organizations to improve efficiency, control, and consistency in production processes. The company offers consumables and instruments such as Protein A ligands, chromatography columns, filtration systems, and analytical tools designed for biologics processing. Headquartered in Waltham, Massachusetts, Repligen Corporation serves customers across North America, Europe, the Asia Pacific, and other international markets, making it an important supplier within the bioprocessing and life sciences tools sector.

CEO Mr. Olivier Loeillot · 2,000 employees · United States · https://www.repligen.com